| Literature DB >> 20617166 |
Zhen Zhang1, Anca Selariu, Charles Warden, Grace Huang, Ying Huang, Oluleke Zaccheus, Tong Cheng, Ningshao Xia, Hua Zhu.
Abstract
The Varicella Zoster Virus (VZV) is a ubiquitous human alpha-herpesvirus that is the causative agent of chicken pox and shingles. Although an attenuated VZV vaccine (v-Oka) has been widely used in children in the United States, chicken pox outbreaks are still seen, and the shingles vaccine only reduces the risk of shingles by 50%. Therefore, VZV still remains an important public health concern. Knowledge of VZV replication and pathogenesis remains limited due to its highly cell-associated nature in cultured cells, the difficulty of generating recombinant viruses, and VZV's almost exclusive tropism for human cells and tissues. In order to circumvent these hurdles, we cloned the entire VZV (p-Oka) genome into a bacterial artificial chromosome that included a dual-reporter system (GFP and luciferase reporter genes). We used PCR-based mutagenesis and the homologous recombination system in the E. coli to individually delete each of the genome's 70 unique ORFs. The collection of viral mutants obtained was systematically examined both in MeWo cells and in cultured human fetal skin organ samples. We use our genome-wide deletion library to provide novel functional annotations to 51% of the VZV proteome. We found 44 out of 70 VZV ORFs to be essential for viral replication. Among the 26 non-essential ORF deletion mutants, eight have discernable growth defects in MeWo. Interestingly, four ORFs were found to be required for viral replication in skin organ cultures, but not in MeWo cells, suggesting their potential roles as skin tropism factors. One of the genes (ORF7) has never been described as a skin tropic factor. The global profiling of the VZV genome gives further insights into the replication and pathogenesis of this virus, which can lead to improved prevention and therapy of chicken pox and shingles.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20617166 PMCID: PMC2895648 DOI: 10.1371/journal.ppat.1000971
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Figure 1Generation of VZV deletion and rescue clones.
A. Generation of the ORFX deletion mutant clone. 1. The E. coli DY380 strain provides a highly efficient homologous recombination system, which allows recombination of homologous sequences as short as 40bp. The homologous recombination system is strictly regulated by a temperature-sensitive repressor, which permits transient switching-on by incubation at 42°C for 15min. VZVluc BAC DNA is introduced into DY380 by electroporation. Electro-competent cells are prepared with homologous recombination system activation. 2. Amplification of the kanR expression cassette by PCR using a primer pair adding 40-bp homologies flanking ORFX. 3. About 200ng of above PCR product are transformed into DY380 carrying the VZVluc BAC via electroporation. 4 and 5. Homologous recombination between upstream and downstream homologies of ORFX replaces ORFX with the KanR cassette, creating the ORFX deletion VZV clone. The recombinants are selected on LB agar plates containing kanamycin at 32°C. 6. The deletion of ORFX DNA is isolated and confirmed by testing antibiotic sensitivity and PCR analysis. The integrity of the viral genome after homologous recombination is examined by restriction enzyme digestion. 7. Purified BAC DNA is transfected into MeWo cells. 8. 3–5 days after transfection the infected cells are visualized by fluorescence microscopy. B. Generation of ORFX rescue virus. 1. To generate the ORFX clone, ORFX was amplified by PCR from the wild-type VZV BAC DNA. 2. ORFX was directionally cloned into plasmid pGEM-lox-zeo to form pGEM-zeo-ORFX. 3. Amplfication of the ORFX-ZeoR cassette by PCR using a primer pair adding 40 bp homologies flanking ORFX. 4. The PCR product was transformed into DY380 carrying the VZVLuc ORFX deletion via electroporation. 5 and 6. Homologous recombination between upstream and downstream homologies of ORFX replaced KanR with the ORFX-ZeoR cassette, creating the ORFX rescue clone. 7. ZeoR and BAC vector sequences were removed while generating virus from BAC DNA (by co-transfecting a Cre recombinase-expressing plasmid).
A list of VZV pOka strain ORFs categorized by the growth properties of their respective deletion mutants in MeWo cells and human fetal skin organ cultures (SOC).
| ORF | Function | HSV-1 Homology | ORF | Function | HSV-1 Homology |
|
|
| ||||
| ORF4R | Transcriptional regulator | UL54 | ORF56S, 1 | Unknown | UL4 |
| ORF5R | Glycoprotein gK3 | UL53 | ORF60S | Glycoprotein gL | UL1 |
| ORF61 | Primase3 | UL52 | ORF612 | Transcriptional regulator | ICP0 |
| ORF9AS, 2 | Envelope glycoprotein protein gN3 | UL49A | ORF62/71D | Transcriptional regulator | ICP4 |
| ORF9 | Tegument pr with unknown function | UL49 | ORF63/70D | Host range factor; Tegument protein | US1 |
| ORF161 | DNA polymerase3 | UL42 | ORF662 | Serine-threonine kinase | US3 |
| ORF172 | Host shut-off factor | UL41 | ORF68 | Glycoprotein gE | US8 |
| ORF201 | Component of intercapsomeric triplex3 | UL38 |
| ||
| ORF21 | Nucleocapsid protein | UL37 | ORF0R | Putative transmembrane protein3 | None |
| ORF221 | Tegument protein with unknown function3 | UL36 | ORF181 | Small subunit of ribonucleotide reductase | UL40 |
| ORF241 | Phosphoprotein3 | UL34 | ORF19 | Large subunit of ribonucleotide reductase | UL39 |
| ORF25S, 1 | DNA packaging protein | UL33 | ORF23 | Small capsid protein | UL35 |
| ORF26S, 1 | DNA packaging protein | UL32 | ORF321 | Probable substrate for ORF47 kinase3 | None |
| ORF27S, 1 | Nuclear matrix protein3 | UL31 | ORF35 | Role in cell to cell fusion | UL24 |
| ORF28S, 1 | DNA polymerase catalytic subunit | UL30 | ORF49S | Role in virion envelopment | UL11 |
| ORF29 | Single-stranded DNA-binding protein | UL29 | ORF67 | Glycoprotein gI | US7 |
| ORF301 | DNA packaging protein | UL28 |
| ||
| ORF311 | Envelope glycoprotein gB | UL27 | ORF7R, 1 | Tegument protein with unknown function3 | UL51 |
| ORF331 | Major capsid scaffold protein | UL26 | ORF10R | Tegument protein; transactivator of IE genes | UL48 |
| ORF33.51 | Minor capsid scaffold protein | UL26.5 | ORF14 | Glycoprotein gC | UL44 |
| ORF341 | DNA packaging protein | UL25 | ORF47S | Serine-threonine kinase | UL13 |
| ORF371 | Glycoprotein gH | UL22 |
| ||
| ORF381 | Tegument protein with unknown function3 | UL21 | ORF1 | Transmembrane protein | None |
| ORF391 | Integral membrane protein3 | UL20 | ORF2 | Unknown | None |
| ORF401 | Component of hexons and pentons | UL19 | ORF3 | Unknown | UL55 |
| ORF411 | Minor capsid protein3 | UL18 | ORF8S | Deoxyuridine triphosphatase | UL50 |
| ORF42/451 | DNA packaging protein | UL15 | ORF11 | Tegument protein with unknown function3 | UL47 |
| ORF431 | DNA packaging protein | UL17 | ORF12 | Tegument protein with unknown function3 | UL46 |
| ORF441 | Tegument pr with unknown function3 | UL16 | ORF13 | Thymidylate synthase | None |
| ORF46S, 1 | Tegument pr with unknown function3 | UL14 | ORF151 | Integral membrane protein3 | UL43 |
| ORF48S, 1 | Deoxyribonuclease3 | UL12 | ORF361 | Deoxypyrimidine kinase | UL23 |
| ORF50S, 1 | Glycoprotein gM3 | UL10 | ORF57 | Tegument protein; role in virion egress3 | None |
| ORF511,4 | Origin binding pr/helicase | UL9 | ORF58 | Unknown | UL3 |
| ORF521 | Component of helicase-primase complex3 | UL8 | ORF59S | Uracil-DNA glycosylase | UL2 |
| ORF531,4 | Tegument protein with unknown function3 | UL7 | ORF64/69D | Tegument pr with unknown function3 | US10 |
| ORF54S, 1 | DNA packaging protein | UL6 | ORF65 | Virion protein involved in axonal transport | US9 |
| ORF55,1 | Helicase3 | UL5 | Essential | ||
Superscript Annotations: “1” corresponds to “results from this study only,” “2” corresponds to “results from this study not consistent with previous studies,” “3” corresponds to “putative function based on homology,” “4” corresponds to “phenotype may be due to effect from adjacent gene,” “S” corresponds to “partial ORF deletion virus study included,” “D” corresponds to “double ORF deletion virus study included,” and “R” corresponds to “Rescue virus study included.”
Figure 2VZV genome-wide functional profiling based on analysis of viral mutants with single open reading frame deletion mutants.
Genomic organization and ORFs arrangement are based on the viral sequence of the VZV pOka strain. Each VZV ORF is color-coded according to the growth properties of its corresponding virus gene-deletion mutant in cultured MeWo cells and human fetal skin organ cultures. The grey lines for ORF42 represent a splicing junction. For all growth curves, wild-type infections served as positive controls and mock infections served as negative controls.
Figure 3Distribution of functional annotations for essential and non-essential genes.
A. Distribution of functional annotations for essential genes. Essential genes are significantly enriched for DNA replication (Bonferroni corrected p-value <10−4) and DNA packing (corrected p-value <10−4) functional categories. B. Distribution of functional annotations for non-essential genes. Non-essential genes are significantly enriched for other (corrected p-value <10−3) and unknown (corrected p-value <0.01) functional categories. Statistical significance was determined by a hypergeometric test.
Figure 4Growth curve analysis of some VZV deletion mutants.
A. Eight VZV ORF deletion mutants showing slow growth kinetics in cultured MeWo cells. One hundred PFU of each deletion mutant and VZVLuc (WT) were infected with MeWo cells in 6-well dishes in triplicate. Bioluminescence was measured using the IVIS system every day for 7 days after D-luciferin was applied to the cultured media. Total Photon Count in each well (photons/sec/cm2/steradian) was measured, and the values from the triplicate results were averaged. The growth curves were generated when averaged photon counts for each day were plotted. Error bars represent standard deviation for three replicates. B. In vitro growth curve analysis of VZV ORF7, ORF10, and ORF47 mutant viruses. One hundred PFU of ORF7 and ORF10 mutant and rescue (ORF7D, ORF7S, ORF7R, ORF10D, and ORF10R) and ORF47 deletion virus (ORF47D) from infected MeWo cells were used to infect 50% confluent MeWos seeded in 6-well dishes. Experiments were performed in triplicates. The growth curves were generated as described in A. C. Growth curve analysis of VZV ORF7, ORF10, and ORF47 mutants in human fetal skin organ cultures. Skin tissues were inoculated with 5×103 PFU VZVLuc or other VZV variants, as indicated. VZV replication was monitored daily by IVIS for one week as bioluminescence emitting from each skin culture was measured. Each line represents an average of the data from 3 different skin tissue samples, all infected with the same virus. D-luciferin was also applied to three uninfected skin tissue samples (injected with PBS) as mock infection.